Gilead's Harvoni Less Expensive, but Still a Burden on State Medicaid Programs
Gilead Sciences' Harvoni represents the first once-a-day, complete treatment pill approved by the FDA to treat the hepatitis C virus (HCV). And for some patients, the drug will be less expensive than Gilead's other HCV treatment, Sovaldi.
Gilead Sciences’ Harvoni represents the first once-a-day, complete treatment pill approved by the FDA to treat the hepatitis C virus (HCV). And for some patients, the drug will be less expensive than Gilead’s other HCV treatment, Sovaldi, which has become the poster child for high-cost specialty drugs.
Sovaldi costs $1000 a pill, for a total of $84,000 for a 12-week course of treatment. However, Sovaldi must be used with other drugs. Harvoni is one pill that comprises a combination of sofosbuvir (Sovaldi) and ledipasvir.
Since Harvoni is being viewed as a replacement for Sovaldi, interferon, and ribavirin, each pill will cost $1125, according to reports from
“By providing very high cure rates in as little as 8 weeks and completely eliminating the need for interferon and ribavirin, which are challenging to take and tolerate, Harvoni significantly advances treatment for patients with the most common form of hepatitis C in the United States,” Nezam Afdhal, MD, director of Hepatology at Beth Israel Deaconess Medical Center, professor of Medicine at Harvard Medical School, and a principal investigator in the Harvoni clinical trials,
Harvoni’s Phase 3 studies evaluated treatment with Harvoni with or without ribavirin for 8, 12, or 24 weeks. For individuals in the ribavirin-free arms, the cure rates were 94-99%. Just 1% or fewer of patients discontinued treatment due to adverse events.
Despite the potentially shorter treatment period, Harvoni’s cost could still be a sticking point. Following Sovaldi’s rollout, 35 states mandated that Medicaid patients needed prior authorization before receiving the drug,
A report from Viohl & Associates, released shortly before the FDA approved Harvoni, highlighted some of the ways states are attempting to curb the use of Sovaldi, including:
- Patients in Alaska must abstain from the use of illicit drugs and alcohol for at least 3 months and will undergo a urine test for verification.
- In some states, such as Arizona, Medicaid patients are only allowed 1 chance at treatment with Sovaldi.
- Illinois only dispenses Sovaldi for 2 weeks at a time with refills available every 2 weeks for the 12-week treatment period.
According to Forbes, it is still unclear how Medicaid programs will handle Harvoni or any other HCV drugs that are expected to receive FDA approval.
Around the Web
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025